Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 79,351 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Peripheral Neuropathy, Diabetes
Interventions: Exercise Program; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Spinal Muscular Atrophy
Interventions: Nusinersen, Sham Procedure; Drug · Procedure
Lead sponsor: Biogen; Industry
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Hartford, Connecticut • Baltimore, Maryland + 3 more

Conditions: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM), Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI), Aicardi-Goutières Syndrome (AGS)
Interventions: Baricitinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic, AML
Interventions: Donor Lymphocyte Infusion, Induction Chemotherapy; Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 1 Year to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lung Neoplasms, Esophageal Lesion
Interventions: Olympus VE2 NIR Imaging System, Indocyanine green; Device · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Not listed
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Antibiotic Treatment
Interventions: autologous fecal matter transplant; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 1 Month to 4 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Chikungunya Virus
Interventions: CHIKV VLP/adjuvant, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 3,258 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 47
States / cities: Huntsville, Alabama • Mobile, Alabama • Tempe, Arizona + 42 more

Conditions: No Condition
Interventions: taVNS, Mindfulness Meditation, low intensity taVNS; Device · Behavioral · Other
Lead sponsor: University of Houston; Other
Eligibility: 18 Years to 29 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Neoplasms
Interventions: CP-751,871, exemestane, Fulvestrant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 33
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 10 more

Conditions: Low Back Pain
Interventions: osteopathic manipulative treatment; Other
Lead sponsor: Ohio University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus; Drug · Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Up to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Stroke, Stroke, Ischemic
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Advanced Melanoma and Normal or Impaired, Advanced Melanoma
Interventions: AB821; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Corneal Persistent Epithelial Defect
Interventions: Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle, Open-label Nexagon® (lufepirsen); Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands
Interventions: Selumetinib, Olaparib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dental Caries in Children
Interventions: Test varnish, Placebo; Drug
Lead sponsor: Advantage Silver Dental Arrest, LLC; Industry
Eligibility: 10 Months to 20 Months
Enrollment: 274 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 0
States / cities: Not listed

Conditions: Metastatic Breast Cancer, Recurrent Breast Cancer
Interventions: Taselisib, Trastuzumab emtansine, Pertuzumab, Trastuzumab, Paclitaxel; Drug
Lead sponsor: Nancy Lin, MD; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 3
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: Diabetes Mellitus
Interventions: non-invasive tissue glucose prediction; Device
Lead sponsor: Sciema UG; Other
Eligibility: 18 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Mateo, California

Conditions: Dermatitis, Chronic
Interventions: clobetasol propionate 0.05%, Vehicle / Placebo; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 10
States / cities: San Diego, California • Boynton Beach, Florida • West Palm Beach, Florida + 6 more

Conditions: Leukemia, CLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Lenalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Major Depressive Disorder
Interventions: CYB003, Psychotherapy, Placebo, Psychological Support; Drug · Behavioral
Lead sponsor: Cybin IRL Limited; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey

Conditions: Depressive Symptoms
Interventions: Freeze-dried Blueberry Powder, Placebo Powder; Other
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Roslindale, Massachusetts

Conditions: Influenza A
Interventions: VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo; Biological
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 2,977 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 51
States / cities: Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 45 more

Conditions: Small Cell Lung Carcinoma
Interventions: Pembrolizumab/Vibostolimab Co-Formulation, Saline placebo, Etoposide, Cisplatin, Atezolizumab, Carboplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 11
States / cities: Mobile, Alabama • Los Angeles, California • Boca Raton, Florida + 7 more

Search by objective public record fields.

Reversing Diabetic Peripheral Neuropathy Through Exercise

A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).

Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

Post Transplant Donor Lymphocyte Infusion

Near-Infrared Perfusion During Minimally Invasive Thoracic Surgery Download

Restoration of Antibiotics Related Infant Microbiota Perturbations by Autologous Fecal Transplant

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)

Stimulating Your Nervous System for Calm (SYNC) Study

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

A Pilot MRI Study of Osteopathic Manipulative Treatment of Acute Low Back Pain

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

Individual Patient Expanded Access IND for the Treatment of Stroke

AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries

Selumetinib and Olaparib in Solid Tumors

Efficacy and Safety Evaluation of Anti-Caries Varnish

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Use of CoG by Patients With Diabetes Mellitus

Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

Berries, Bugs, and the Blues

A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)